论文部分内容阅读
移植后恶性血液病复发是异基因造血干细胞移植失败的主要原因之一,国际骨髓移植登记组(CIBMTR)的最新资料显示,恶性血液病复发在同胞相合和非血缘移植后的死因中占48%和37%。最近北京大学血液病研究所的资料显示,同胞相合和单倍型移植后的复发相关死亡率在总体人群中分别为17%和16%,在死因中分别占42%和32%~([1])。有效防治移植后复发是提高移植疗效的
The recurrence of hematologic malignancies after transplantation is one of the major causes of allogeneic hematopoietic stem cell transplantation failure. The latest information from the International Marrow Transplant Registry (CIBMTR) shows that the recurrence of hematologic malignancies accounts for 48% of the deaths after sibling and non- And 37%. Recent data from Peking University Institute of Hematology showed that relapse-related mortality after sibling and haploidentical transplantation was 17% and 16%, respectively, in the general population and 42% and 32%, respectively, in the cause of death ]). Effective prevention and treatment of post-transplant recurrence is to improve the efficacy of transplantation